<DOC>
	<DOCNO>NCT02102542</DOCNO>
	<brief_summary>This observational study design prove clinical efficacy well know `` glycopyrrolate '' consider orphan drug Thailand . Since medication never officially use Thai people particular brand `` Glyco-P '' make India never officially proven efficacy Thai people . The study aim prove Glyco-P modestly increase patient 's heart rate , decrease secretion safely use combination neostigmine reversal non-depo muscle relaxant drug .</brief_summary>
	<brief_title>Efficacy Intravenous Glyco-P® Patients Undergoing Procedure That Require Anesthesia Service</brief_title>
	<detailed_description>Background rationale Glycopyrrolate long use since 's first discovery 19602 . The medication generally available oral injectable form . The uses glycopyrrolate anesthesia mainly reduction salivation secretion3 , play significant role airway instrumentation require . The widespread us neostigmine reversal muscle relaxant effect cause non-depolarizing muscle relaxant also mandate co-administration anti-muscarinic4,5,6 . Without availability glycopyrrolate , atropine use Thailand , result excessive tachycardia salivation7,8,9 . Glycopyrrolate also use mild bradycardia encounter effect heart rate less dominant atropine10,11 . Glycopyrrolate consider orphan drug Thailand . There simply availability recently . The local company name `` Masu '' decide market import drug India ( Glyco-P® ) . The formulary approve Thai Food Drug Administration1 . The preparation also test laboratory third party well-known pharmacy institute , prove existence active ingredient . However , use medication officially make appropriate action obtain IRB approval local institution consent patient prior drug administration . The appropriate record clinical effect also make . Objective 1 . Evaluate clinical efficacy glycopyrrolate heart rate , anti-sialagogue effect use conjunction neostigmine reversal neuromuscular blockade . 2 . Evaluate timing , onset duration glycopyrrolate injection different dose . Materials , participant study method The study require 1 . 100 patient schedule undergo procedure operation require anesthesia service meet criterion use glycopyrrolate include - requirement anti-sialogogue , mild bradycardia receive neostigmine reversal neuromuscular block agent . 2 . Glyco-P injection 3 . Monitorings capable HR , BP measurement 4 . Suctioning equipment volumetric measurement 5 . Clinician evaluate effect medication 6 . Timer Participants : - 100 adult male female patient , 18 year old consent study . Exclusion Criteria : Children &lt; 18 yo , pregnant parturient breast feeding patient , patient refuse unable give consent , patient co-existing problem dry secretion i.e . Sjögren 's syndrome , glaucoma , myasthenia gravis , patient baseline heart rate &gt; 100 bpm Study method 1 . The patient meet inclusion criterion consent receive medication . 2 . The medication administer 1 criterion meet - To increase heart rate modestly - For reduction secretion salivation - To co-administration neostigmine 3 . The medication give follow fashion - Glyco-P 4 mcg/kg IV , repeatedly effect . Halt HR &gt; 100 bpm - Glyco-P 0.2 mg per mg neostigmine use 4 . The clinical effect i.e . heart rate , blood pressure , amount secretion remove record along time onset offset . 5 . Collected data analyze statistician appropriate statistical method . Data analysis 1 . Demographic data participant 2 . Dose indication treatment study drug 3 . Timing clinical effect 4 . Changes heart rate blood pressure 5 . Efficacy reduction saliva secretion Duration study 3 month Benefit study Confirmation clinical efficacy Indian make glycopyrrolate - Glyco-P® Thai patient . Other institution participation None</detailed_description>
	<mesh_term>Bradycardia</mesh_term>
	<mesh_term>Muscle Hypotonia</mesh_term>
	<mesh_term>Sialorrhea</mesh_term>
	<mesh_term>Neuromuscular Blocking Agents</mesh_term>
	<criteria>adult 18 year age , undergoing procedure require anesthesia service . meet criteria prevention drooling , hypersalivation bradycardia require reversal muscle relaxant . child &lt; 18 year old , pregnant parturient breast feeding patient , patient refuse unable give consent , patient coexist problem dry secretion ( i.e . Sjögren 's syndrome , glaucoma , myasthenia gravis ) , patient baseline heart rate &gt; 100 bpm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>glycopyrrolate</keyword>
	<keyword>efficacy</keyword>
	<keyword>antisialagogue</keyword>
</DOC>